← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Rise Therapeutics, Llc
Rockville, MD
$31,609,425
Total funding
18
Grants
Funding over time
peak $7.5M · FY2018–25$10M$7.5M$5M$2.5M$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$31,609,425 · 18
By mechanism
R44$25,304,043 · 11
SB1$4,296,366 · 2
R43$1,579,858 · 4
UG3$429,158 · 1
Investigators at Rise Therapeutics, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
A Novel Microbiome-Based Immune-Modulator that Potentiates Cancer Checkpoint Therapy$1,049,717
R44 · FY2022 · CA
A Novel Synthetic Biology-Derived Microbiome Therapeutic to Treat Viral-Induced Acute Respiratory Distress Syndrome (ARDS)$1,026,596
R44 · FY2023 · AI
A Novel Immunologically Directed Probiotic for the Treatment of Type 1 Diabetes$1,021,316
R44 · FY2022 · DK
A Novel Immunological-Directed Live Biotherapy Product for Treating Ulcerative Colitis$1,001,952
R44 · FY2023 · DK
R-5280, A Novel Modified Superior Resistant Starch Therapy for Type 1 Diabetes$1,000,000
R44 · FY2023 · DK
A Novel Immunologically Enhanced Probiotic for Treating Rheumatoid Arthritis$1,000,000
R44 · FY2022 · AI
A Novel Immunologically Enhanced Probiotic for Treating Rheumatoid Arthritis$1,000,000
R44 · FY2021 · AI
A Novel Probiotic for the Treatment of Sjogren's Syndrome$998,658
SB1 · FY2021 · DE
R-5280, A Novel Modified Superior Resistant Starch Therapy for Type 1 Diabetes$995,869
R44 · FY2024 · DK
A Novel Immunological-Directed Biotherapy for Treating Rheumatoid Arthritis$987,225
R44 · FY2024 · AG
A Novel Synthetic Biology-Derived Microbiome Therapeutic to Treat Viral-Induced Acute Respiratory Distress Syndrome (ARDS)$984,405
R44 · FY2024 · AI
A Novel Immunologically Directed Probiotic for the Treatment of Type 1 Diabetes$983,580
R44 · FY2023 · DK
A Novel Engineered Probiotic for the Prevention of Clostridium Difficile Infection$973,438
R44 · FY2022 · AI
A Novel Probiotic for the Treatment of Sjogren's Syndrome$972,063
SB1 · FY2022 · DE
A Novel Engineered Probiotic for the Prevention of Clostridium Difficile Infection$957,796
R44 · FY2020 · AI
A Novel Probiotic for the Treatment of Sjogren's Syndrome$956,644
R44 · FY2019 · DE
A Novel Immunological-Directed Synthetic Biology-Based Drug for the Treatment of Multiple Sclerosis$956,049
R44 · FY2024 · AI
A Novel Immunological-Directed Biotherapy for Treating Rheumatoid Arthritis$952,967
R44 · FY2025 · AG
A Novel Probiotic for the Treatment of Sjogren's Syndrome$949,519
R44 · FY2020 · DE
A Novel Probiotic for the Treatment of Sjogren's Syndrome$947,701
SB1 · FY2023 · DE